Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug enters first human trials for advanced tumors

NCT ID NCT06234397

Recruiting now Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

Summary

This is the first human study of a new cancer drug called BH3120. Researchers are testing it alone and combined with an existing immunotherapy (pembrolizumab) in 245 patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find safe doses and see if the treatment shows early signs of helping control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • Mary Crowley Cancer Research

    WITHDRAWN

    Dallas, Texas, 75230, United States

  • Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cencer Center

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

  • The START Center for Cancer Care - Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS